140 related articles for article (PubMed ID: 24126726)
41. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.
Hurst NJ; Najy AJ; Ustach CV; Movilla L; Kim HR
Biochem J; 2012 Feb; 441(3):909-18. PubMed ID: 22035541
[TBL] [Abstract][Full Text] [Related]
42. EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.
Bougatef F; Menashi S; Khayati F; Naïmi B; Porcher R; Podgorniak MP; Millot G; Janin A; Calvo F; Lebbé C; Mourah S
PLoS One; 2010 Aug; 5(8):e12265. PubMed ID: 20824203
[TBL] [Abstract][Full Text] [Related]
43. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor.
Graeven U; Rodeck U; Karpinski S; Jost M; Philippou S; Schmiegel W
Cancer Res; 2001 Oct; 61(19):7282-90. PubMed ID: 11585767
[TBL] [Abstract][Full Text] [Related]
44. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.
Nykänen AI; Krebs R; Tikkanen JM; Raisky O; Sihvola R; Wood J; Koskinen PK; Lemström KB
Transplantation; 2005 Jan; 79(2):182-9. PubMed ID: 15665766
[TBL] [Abstract][Full Text] [Related]
45. Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
Hong X; Jiang F; Kalkanis SN; Zhang ZG; Zhang X; Zheng X; Mikkelsen T; Jiang H; Chopp M
J Exp Ther Oncol; 2007; 6(3):219-29. PubMed ID: 17552362
[TBL] [Abstract][Full Text] [Related]
46. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism.
Potapova O; Fakhrai H; Mercola D
Int J Cancer; 1996 May; 66(5):669-77. PubMed ID: 8647631
[TBL] [Abstract][Full Text] [Related]
47. MMP inhibition blocks fibroblast-dependent skin cancer invasion, reduces vascularization and alters VEGF-A and PDGF-BB expression.
Woenne EC; Lederle W; Zwick S; Palmowski M; Krell H; Semmler W; Mueller MM; Kiessling F
Anticancer Res; 2010 Mar; 30(3):703-11. PubMed ID: 20392987
[TBL] [Abstract][Full Text] [Related]
48. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma.
Rofstad EK; Danielsen T
Br J Cancer; 1998 Mar; 77(6):897-902. PubMed ID: 9528831
[TBL] [Abstract][Full Text] [Related]
49. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids.
Nauck M; Roth M; Tamm M; Eickelberg O; Wieland H; Stulz P; Perruchoud AP
Am J Respir Cell Mol Biol; 1997 Apr; 16(4):398-406. PubMed ID: 9115750
[TBL] [Abstract][Full Text] [Related]
50. PDGF-D signaling: a novel target in cancer therapy.
Wang Z; Kong D; Li Y; Sarkar FH
Curr Drug Targets; 2009 Jan; 10(1):38-41. PubMed ID: 19149534
[TBL] [Abstract][Full Text] [Related]
51. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
52. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
53. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
[TBL] [Abstract][Full Text] [Related]
54. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.
Li CY; Wang Q; Wang XM; Li GX; Shen S; Wei XL
Eur J Pharmacol; 2019 Dec; 864():172719. PubMed ID: 31586634
[TBL] [Abstract][Full Text] [Related]
55. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
56. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
Deryugina EI; Soroceanu L; Strongin AY
Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
Anan K; Morisaki T; Katano M; Ikubo A; Kitsuki H; Uchiyama A; Kuroki S; Tanaka M; Torisu M
Surgery; 1996 Mar; 119(3):333-9. PubMed ID: 8619189
[TBL] [Abstract][Full Text] [Related]
59. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
